Kodiak Sciences Inc (KOD)
NASDAQ:KOD
Want to see KOD full AI Analyst Report?
KOD Stock Chart & Stats
$44.90
-$0.42(-4.39%)
At close: 4:00 PM EST
$44.90
-$0.42(-4.39%)
Day’s Range― - ―
52-Week Range$3.26 - $47.84
Previous CloseN/A
Volume87.32K
Average Volume (3M)660.44K
Market Cap
$2.30B
Enterprise Value$1.83B
Total Cash (Recent Filing)$169.53M
Total Debt (Recent Filing)$55.99M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Aug 19, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding62,578,440
10 Day Avg. Volume631,820
30 Day Avg. Volume660,436
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.45
Price to Sales (P/S)0.00
P/FCF Ratio-10.90
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.94
Forecast
1Y Price Target
$62.67Price Target Upside39.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durability And Dosing AdvantageThe antibody biopolymer conjugate design combines immediate and long-acting components, supporting less frequent dosing and a potential commercial differentiation from current anti-VEGF therapies.
Phase 3 Clinical ValidationPositive Phase 3 GLOW2 topline results validated the reformulated drug's clinical profile by demonstrating efficacy versus control and increased confidence in the trial outcomes.
Regulatory PathwayTarcocimab and Zenkuda are positioned for regulatory filing with the programs described as BLA-ready, and a regulatory trend toward approving drugs based on a single adequate study could enable an accelerated approval route.
Bears Say
Financial RunwayHigh cash burn combined with limited cash resources creates significant financing risk and increases the likelihood that additional funding will be needed before sustained revenue is achieved.
Investor Sentiment And VolatilityMeaningful short interest and investor skepticism signal market doubts about clinical and commercial prospects and may contribute to elevated share-price volatility.
Legacy Formulation RiskA prior formulation produced higher cataract rates that muddied visual acuity results, leaving lingering doubts about the reliability of earlier late-stage data.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences Inc’s price range in the past 12 months?
Kodiak Sciences Inc lowest stock price was $3.26 and its highest was $47.84 in the past 12 months.
What is Kodiak Sciences Inc’s market cap?
Kodiak Sciences Inc’s market cap is $2.30B.
When is Kodiak Sciences Inc’s upcoming earnings report date?
Kodiak Sciences Inc’s upcoming earnings report date is Aug 19, 2026 which is in 79 days.
How were Kodiak Sciences Inc’s earnings last quarter?
Currently, no data Available
Is Kodiak Sciences Inc overvalued?
According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued.
Does Kodiak Sciences Inc pay dividends?
Kodiak Sciences Inc does not currently pay dividends.
What is Kodiak Sciences Inc’s EPS estimate?
Kodiak Sciences Inc’s EPS estimate is -0.96.
How many shares outstanding does Kodiak Sciences Inc have?
Kodiak Sciences Inc has 62,578,440 shares outstanding.
What happened to Kodiak Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kodiak Sciences Inc?
Currently, no hedge funds are holding shares in KOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kodiak Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.67 (39.57% Upside)
$62.67 (39.57% Upside)
Hedge Fund Trend
Decreased
By 868.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
433.33%
12-Months-Change
Fundamentals
Return on Equity
-253.85%
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Company Description
Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
KOD Stock 12 Month Forecast
Average Price Target
$62.67
▲(39.57% Upside)
Technical Analysis
Urogen Pharma
―
Nurix Therapeutics
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
33.51% Insiders
9.69% Mutual Funds
5.00% Other Institutional Investors
41.39% Public Companies and
Individual Investors